EricJ.SmallMD

Genitourinary Oncology, Hematologic Oncology

Director, Investigational Trials Resource, UCSF Helen Diller Family Comprehensive Cancer Center; Chief, Division of Hematology/Oncology, UCSF; Deputy Director and Director of Clinical Sciences, UCSF Helen Diller Family Comprehensive Cancer Center

Join to view full profile

Dr. Small is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Small's full profile

Already have an account?

Office
1600 Divisadero St
San Francisco, CA 94143
Phone+1 415-353-7171

Fax+1 415-353-7093

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1988 - 1989
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1985 - 1988
Case Western Reserve University School of MedicineClass of 1985

Certifications & Licensure

CA State Medical License 1987 - 2026
American Board of Internal Medicine Internal Medicine
National Board of Physicians and Surgeons Internal Medicine
National Board of Physicians and Surgeons Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2004-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors Start of enrollment: 1994 Sep 01
Completed
Phase 3
SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer Start of enrollment: 1995 May 01
Completed
Phase 3
Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer Start of enrollment: 1996 Jan 01
Completed
Phase 3
Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer Start of enrollment: 1996 Aug 01
Completed
Phase 3
S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy Start of enrollment: 1999 Oct 01
Completed
Phase 3
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy Start of enrollment: 1999 Nov 01
Completed
Phase 3
APC8015 and Bevacizumab in Treating Patients With Prostate Cancer Start of enrollment: 2001 Dec 01
Completed
Phase 2
Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer Start of enrollment: 2005 Feb 01
Terminated
Phase 1, Phase 2
Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC) Start of enrollment: 2007 Apr 01
Completed
Phase 2
Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer Start of enrollment: 2004 Mar 01
Completed
Phase 1
Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA) Start of enrollment: 1999 Apr 01
Completed
Phase 2
Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy Start of enrollment: 2011 Jan 01
Completed
Phase 2
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy Start of enrollment: 2014 Feb 05
Active, not recruiting
Phase 2
Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2014 Sep 02
Terminated
Phase 2
Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide Start of enrollment: 2013 Mar 12
Completed
Join now to see all

Publications & Presentations

PubMed

2 citations
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).
Silke Gillessen, Fabio Turco, Ian D Davis, Jason A Efstathiou, Karim Fizazi
European Urology. 2025-02-01
Digital Pathology-Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate ...
Felix Y Feng, Matthew R Smith, Fred Saad, Pooya Mobadersany, Shaozhou K Tian
JCO Precision Oncology. 2025-01-01
1 citations
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors.
Jonathan Chou, Troy M Robinson, Emily A Egusa, Roshan Lodha, Meng Zhang
Clinical Cancer Research. 2024-12-02

Journal Articles

First-in-Human Phase I Study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer
Spencer C Behr, Hao G Nguyen, Thomas A Hope, Kirsten L Greene, Matthew R Cooperberg, Robert R Flavell, Eric J Small, Peter R Carroll, Journal of Nuclear Medicine
Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised ...
Toni K Choueiri, Olwen Hahn, Thomas Olencki, Eric J Small, Shaker Dakhil, Darren R Feldman, European Journal of Cancer
Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival
Eric J Small, David I Quinn, Clinical Cancer Research

Lectures

Efficacy of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) and ba...
2019 ASCO Annual Meeting - 6/1/2019

Authored Content

Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival Update’ [Eur J Cancer 94 (May 2018) 115–125]September 2018
Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival UpdateApril 2018

Press Mentions

Felix Feng, Giant in the Field of Prostate Cancer, Dies at 48January 22nd, 2025
NEUVOGEN Appoints Dr. Mark W. Frohlich, a World-Renowned Immunotherapy Expert to Its Board of Directors and Scientific Advisory BoardAugust 23rd, 2021
Trial Update for Apalutamide in Nonmetastatic Castration-Resistant Prostate CancerFebruary 14th, 2019
Join now to see all

Grant Support

Prostate Cancer ProgramNational Cancer Institute2007–2011
04557: A Phase I/II Study Of Docetaxel/Prednisone And PTK 787/Zk 222584 In PRNational Center For Research Resources2005
Effects Of Bicalutamide Monotherapy On Bone Density In Prostate CancerNational Center For Research Resources2004–2005
Evaluation Of Continuous Infusion Gallium Nitrate For Advanced Bladder CarcinomaNational Center For Research Resources1997
Study Of Pyrazoloacridine For Treatment Of Hormone Refractory Prostate CancerNational Center For Research Resources1996–1997
Evaluation Of Continuous Infusion Gallium Nitrate For Advanced Bladder CancerNational Center For Research Resources1996